WASHINGTON, August 5, 2026. Drug repurposing moved into the regulatory spotlight as the Reagan-Udall Foundation for the FDA convened a public meeting on how to identify and prioritise new uses for medicines that are already approved.

The meeting addressed a deceptively difficult question. If a medicine already has an established safety profile, manufacturing process and body of clinical experience, what additional evidence should be required before it is used for a new disease, a new patient group or a different stage of treatment?

FDA described repurposing as a potential route to faster patient access because development can build on information that already exists. That foundation can remove some early uncertainty, but it does not answer whether the product works in the proposed new setting. Dose, duration, interactions, disease biology and the characteristics of the target population can all change the benefit-risk calculation.

A prioritisation problem, not just a scientific one

The central challenge is deciding which opportunities deserve scarce research capacity. Candidates may emerge from academic studies, clinician experience, patient groups, real-world data, computational screening or unexpected findings in completed trials. A transparent framework could help distinguish plausible signals from hypotheses that are attractive mainly because an approved product is readily available.

Useful criteria could include biological rationale, strength and consistency of existing evidence, unmet medical need, feasibility of a definitive trial and the likelihood that a successful programme would translate into access. The last point matters. Older or off-patent medicines may lack a conventional commercial sponsor even when the public-health case for investigation is strong.

Evidence still has to fit the claim

Repurposing can shorten parts of development, but it cannot eliminate the need for evidence matched to the new claim. A familiar medicine may behave differently in children, older adults or patients taking complex combinations. A lower dose may be effective for one condition but inadequate for another. Safety events considered acceptable in a life-threatening cancer could be unacceptable in a chronic, less severe disease.

Regulators therefore need flexibility about which existing data can be bridged while remaining clear about what must be newly generated. Randomised trials will remain important for many questions, particularly where observational data are vulnerable to confounding. External controls, pragmatic trials and real-world evidence may add value when their limitations are explicit and the endpoint is reliable.

Execution will determine whether repurposing scales

Even a strong framework will require sponsors, investigators, patient organisations, funders and regulators to coordinate early. Protocol design, product supply, intellectual property, data ownership and post-approval responsibilities can become obstacles when no single organisation controls the programme.

For clinical-development teams, the policy discussion is a reminder that operational speed depends on evidence planning. Australia and New Zealand can contribute through experienced sites, diverse patient access and established ethics and regulatory pathways, but any global strategy still needs a dataset built for the intended regulator and label.

The meeting does not by itself create a new approval pathway. It does, however, sharpen an increasingly important policy agenda: how to turn credible repurposing signals into trials that are fast enough to matter and rigorous enough to trust.